semaglutide increases risk of what A new study showed that use the GLP1 agonist medications approved for diabetes and weight loss including liraglutide (Victoza, Saxenda) & (Ozempic, Wegovy, Rybelsus) come with a 9X increased Cardiovascular outcomes of semaglutide and

Anti-diabetic medication (ADM) prescribing increased from December 2024 to January 2025, then remained relatively stable until March 2025

Under the headship of our mentor Mr

Frequently Asked Questions Can I stop taking GLP-1 medication once I reach my goal weight

Yet, many myths surround who should be prescribed these drugs, how they work and what they can and cannot do

They are sold strictly as: Research chemicals Laboratory compounds Not for human consumption Not for medical use Benefits Observed in Preclinical Research (Animal Models Only) While human studies are limited, preclinical research suggests potential involvement in: Tissue repair signaling Cellular regeneration response Inflammation modulation pathways Collagen and connective tissue activity Angiogenic signaling mechanisms However, these findings do not confirm human efficacy